Pharmaxis Ltd. announced that its cystic-fibrosis drug, Bronchitol, met the primary and secondary goals during a late stage clinical trial. More than 300 patients received 400 mg of Bronchitol twice daily for half a year, and their lung function improved at week 6, which was sustained through week 26. In addition, Bronchitol improved the lung function in patients who already were treated for cystic fibrosis with Genentech"s Pulmozyme (dornase alfa).
저작권자 © 메디칼업저버 무단전재 및 재배포 금지